If you take ADHD medication and you’re considering rehab, or you’re already in treatment and wondering what happens to your prescription, you’re probably asking a question that feels important and strangely hard to get a clear answer to. This page covers what the research shows about ADHD medication and addiction risk, and what actually happens at Abbington House when someone arrives with an ADHD prescription.
This page is written from clinical experience at Abbington House and draws on current published research. It is intended to inform decision-making, not to replace personal medical advice. Anyone making changes to ADHD medication should do so in conversation with their prescriber.
What the research actually shows
The clearest evidence on ADHD medication and addiction risk comes from a Swedish national study published in the British Medical Journal in 2024. Researchers tracked more than 148,000 adults with ADHD and compared outcomes between those receiving prescribed medication and those who weren’t (BMJ, 2024).
The findings were significant. People with ADHD who were receiving prescribed medication showed:
- A 25% reduction in repeat episodes of substance misuse
- A 17% reduction in first-time suicidal behaviour
- Up to a 16% reduction in transport accidents
- Up to a 25% reduction in criminal behaviour
This sits within a broader body of research consistently finding that, for adults with ADHD, properly managed medication tends to reduce rather than increase substance use risk. A 2014 meta-analysis covering multiple studies reached the same overall conclusion (Humphreys et al., 2013).
Untreated ADHD appears to carry meaningfully higher addiction risk than treated ADHD.
The long-standing fear that prescribing a stimulant to someone with ADHD will increase their addiction risk isn’t supported by the evidence.
Why ADHD medication reduces relapse risk
Understanding why medication helps requires understanding what ADHD does to the brain in the first place.
ADHD affects the dopamine reward system. Baseline dopamine sits lower than in neurotypical brains, which means motivation, focus, and the ability to feel satisfied by everyday experiences are all affected. For many people, the brain feels chronically under-stimulated. This is why people with untreated ADHD often gravitate toward substances or compulsive behaviours that deliver fast dopamine. The substance is meeting a regulation need the nervous system can’t meet on its own.
For a deeper look at the connection between ADHD and addiction generally, see our piece on ADHD and addiction.
Prescribed ADHD medication works on the same dopamine pathways but in a controlled, sustained, therapeutic way. Stimulants like methylphenidate and lisdexamfetamine raise dopamine activity steadily over hours rather than in the brief, intense spikes that recreational substances produce. Non-stimulant options like atomoxetine and guanfacine work through different mechanisms but with the same underlying goal: stabilising attention, reducing impulsivity, and creating enough internal regulation that the person doesn’t have to seek it externally.
When this works, several things change for someone in recovery:
- Impulsivity reduces, which lowers the risk of “just this once” decisions during cravings
- Emotional regulation improves, reducing the intensity of difficult states that often drive use
- Focus increases, making therapy more effective
- The chronic background under-stimulation that drove substance use in the first place becomes less acute
None of this is automatic. Medication doesn’t replace therapy, structure, or recovery work. But it can create the conditions under which all of those become more possible.
The stimulant question: is ADHD medication addictive?
This is the question that worries people most, and it deserves a clear answer.
Stimulant ADHD medications, including methylphenidate (Ritalin, Concerta) and lisdexamfetamine (Elvanse), are controlled drugs. They have abuse potential if used outside their prescribed indication. That risk is real and that’s why prescriptions are carefully managed.
For someone with diagnosed ADHD, taking the medication as prescribed, the picture looks very different. Therapeutic doses, taken consistently and orally, don’t produce the rapid dopamine spike that drives addiction. The medication brings the dopamine system into a more normal operating range rather than pushing it into reward-seeking territory.
The research is consistent on this point. Adults with ADHD on prescribed medication are not more likely to develop substance use disorders than adults with ADHD who aren’t medicated. The available evidence suggests the opposite: medication tends to be protective.
Where the picture becomes more complex is when someone has a history of stimulant addiction specifically — cocaine, amphetamine, crack, or misuse of prescription stimulants. In these cases, prescribing further stimulants can be clinically inappropriate. Non-stimulant ADHD medications exist precisely for situations like this. The decision belongs with the prescriber, made in full knowledge of the person’s substance history.
ADHD medication during residential treatment at Abbington House
People sometimes assume that arriving at a residential rehab means stopping all medication on day one. That isn’t how Abbington House works.
If someone arrives with a valid ADHD prescription, the medication isn’t automatically stopped. It’s reviewed clinically, alongside the person’s substance history and the wider treatment plan. The decision is made case by case, taking the following into account:
- Substance history. Someone with a history of cocaine, amphetamine, or stimulant misuse is in a different position to someone whose addiction is to alcohol, cannabis, or opioids. Stimulant medications carry different clinical risk depending on what’s been used and how recently.
- Current prescription. Whether the medication is a stimulant or non-stimulant, the dose, and how stable the person has been on it.
- The prescriber. Whether the medication has been managed by an NHS service, an independent psychiatrist, or under a shared-care arrangement, and whether we can liaise with them during treatment.
- Stage of treatment. Detox creates different physiological conditions than later phases of treatment. Medication that’s appropriate in week three may need pausing during acute withdrawal.
- How the person feels about it. Some people arriving for treatment want a break from stimulants regardless. Others rely on their medication to function. Both perspectives matter.
What this means in practice: the conversation about ADHD medication is part of the admissions process, not a surprise on arrival. Anyone with an active prescription is encouraged to mention it before admission so the clinical team can review it ahead of time and avoid disruption.
For some people, ADHD medication continues uninterrupted through residential treatment. For others, it’s adjusted, paused, or restarted at a different point. The principle underneath is straightforward: medication decisions are made clinically, in conversation with the person, rather than by blanket policy.
For a fuller picture of how ADHD is supported during residential treatment beyond just medication, see our page on ADHD and residential rehab.
What to do if you take ADHD medication and are considering rehab
A few practical points worth knowing.
Don’t stop your medication unilaterally. Stopping ADHD medication suddenly, particularly stimulants, can cause significant rebound symptoms — fatigue, low mood, concentration difficulties, sometimes flat depression. None of this helps someone preparing for treatment. Any changes to ADHD medication should be made in conversation with your prescriber.
Mention it during admissions. When you call any residential treatment provider, including Abbington House, name your current ADHD medication, dose, and prescriber. This lets the clinical team plan ahead. It also avoids the awkward situation of arriving at treatment without enough medication to bridge the first few days.
Bring the prescription, not just the medication. Treatment centres need to see the prescription paperwork, not just a pill bottle. If your prescription is held electronically, bring the relevant documentation.
Ask the specific question. If you want to know whether a particular provider will continue your prescription, ask directly. “I take 30mg of Elvanse daily, prescribed by [provider]. Will that continue during treatment?” gets you a clearer answer than asking in general terms.
Be open about substance history. If you’ve misused stimulants — your own ADHD medication or others’ — being honest about this with the admissions team helps the clinical decision rather than complicating it. Concealment tends to produce worse outcomes than disclosure.
Questions people often ask
Will I have to stop my ADHD medication if I go to rehab?
Not automatically. At Abbington House, ADHD medication is reviewed clinically based on each person’s substance history, current prescription, and treatment plan. For many people, the medication continues through treatment. For some, particularly those with stimulant misuse histories, it’s adjusted or paused. The decision is made in conversation with the person and where possible with their prescriber.
What if my addiction is to stimulants?
This is the situation where prescribing decisions become most careful. Continuing a stimulant ADHD medication during treatment for stimulant addiction is sometimes clinically inappropriate. Non-stimulant ADHD medications, including atomoxetine and guanfacine, exist for exactly this reason and may be considered. The decision is made by the clinical team based on the specific substance history and prescription.
Is it worth getting an ADHD diagnosis before going to rehab?
Not necessarily. Many people only discover their ADHD during or after addiction treatment. Diagnostic waiting times in the UK are often long, and treatment shouldn’t be delayed waiting for a diagnosis. If you suspect ADHD is part of your picture, mention it to the treatment team. ADHD-aware care doesn’t require a formal diagnosis to begin.
Can ADHD medication trigger a relapse?
For most people with ADHD, the evidence suggests medication reduces relapse risk rather than increasing it. The exception is people with stimulant misuse histories, where prescribing stimulants can create additional risk. Non-stimulant options remove that specific concern. Anyone worried about this should raise it directly with their prescriber and treatment team.
If you’re considering treatment
If you take ADHD medication and you’re thinking about residential treatment, the most useful first step is usually a conversation with the admissions team. Bring your prescription details. Mention any concerns about how your medication might be handled. Ask the specific questions you have.
At Abbington House, those conversations happen before admission rather than on arrival. The aim is for anyone considering treatment to know in advance how their medication will be managed, what the clinical team’s view is, and what the options are.
Related: ADHD and Addiction: The Connection · ADHD and Residential Rehab · Contact Us
References
- Lichtenstein, P., et al. (2024). Long-term risk of major outcomes in individuals with attention-deficit/hyperactivity disorder receiving medication: cohort study. British Medical Journal. Available at: bmj.com/content/390/bmj-2024-083658
- Humphreys, K. L., Eng, T., & Lee, S. S. (2013). Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry, 70(7), 740-749.